April 29, 2021
Lancet Haematology Journal Commentary: Sevuparin trial for acute pain in sickle cell disease: the dog that did not bark
We might never know the answer to these specific questions, but we should continue to document realworld findings, particularly regarding the risks and benefits of voxelotor to end-organ function. Building on preclinical models,7 preliminary studies showing preserved or lowered cerebral blood flow,8 together with the results of this study1 and ongoing studies, such as HOPE …